Alpha Cognition Inc
ACOG
Classifica tra le azioni
#20188
Alpha Cognition Inc., a biopharmaceutical company, engages in the development... Alpha Cognition Inc., a biopharmaceutical company, engages in the development of treatments for patients suffering from neurodegenerative diseases in the United States and Canada. The company's commercial development program includes ZUNVEYL oral tablet formulation for treating Alzheimer's disease. Its pre-clinical development programs comprise ZUNVEYL in combination with memantine for the treatment of moderate-to-severe Alzheimer's disease; ALPHA-1062 sublingual formulation for acute pancreatitis; ALPHA-1062 intranasal formulation for the treatment of cognitive impairment with mild traumatic brain injury; and ALPHA-0602, ALPHA-0702, and ALPHA-0802 programs for the treatment of neurodegenerative diseases, including amyotrophic lateral sclerosis disease and spinal muscular atrophy. The company was founded in 2000 and is headquartered in Vancouver, Canada.
Prezzo delle azioni
$8.47
Ultima sincronizzazione: 2026-10-19
Capitalizzazione di mercato
$131.47M
Variazione (1 giorno)
3.36%
Variazione (1 anno)
68.29%
Paese
US
Scambia Alpha Cognition Inc (ACOG)
Categoria
Healthcare
Rapporto P/S per Alpha Cognition Inc (ACOG)
Rapporto P/S al October 2026 TTM: 0.00
Secondo gli ultimi rapporti finanziari e il prezzo delle azioni di Alpha Cognition Inc, il rapporto P/S attuale (TTM) è 0.00. Alla fine del 2022, era pari a 0.00.
Storico del rapporto P/S per Alpha Cognition Inc da 2018 a 2026
Rapporto P/S alla fine di ogni anno
| Anno | Rapporto P/S | Cambia |
|---|---|---|
| 2026 (TTM) | 0.00 | 0.00% |
| 2023 | 0.00 | 0.00% |
| 2022 | 0.00 | 0.00% |
| 2021 | 0.00 | 0.00% |
| 2020 | 0.00 | 0.00% |
| 2019 | 0.00 | 0.00% |
| 2018 | 0.00 | 0.00% |
Rapporto P/S per aziende simili o concorrenti
| Azienda | Rapporto P/S | Differenza del rapporto P/S | Il paese |
|---|---|---|---|
| 10.02 | - |
US
|
|
| 40.55 | - |
US
|
|
| 3.96 | - |
AU
|
|
| - | - |
CH
|
|
| 10.15 | - |
NL
|
